Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

ClinicalTrials.gov ID: NCT03016819

Public ClinicalTrials.gov record NCT03016819. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Study identification

NCT ID: NCT03016819
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Advenchen Laboratories, LLC; Industry
Enrollment: 325 participants

Conditions and interventions

Conditions

Interventions

AL3818 Drug
AL3818 or placebo Drug
Dacarbazine Drug
Digoxin (0.25mg) Drug
Midazolam 2 mg for CYP3A4 phenotyping Drug
Rosuvastatin 10 mg tablet. Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 14, 2017
Primary completion: Nov 30, 2027
Completion: Nov 30, 2028
Last update posted: Feb 24, 2026

2017 – 2028

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Mayo Clinic Arizona	Phoenix	Arizona	85054	Completed
University of California Los Angeles	Los Angeles	California	90404	Completed
Sarcoma Oncology Center	Santa Monica	California	90403	Recruiting
Stanford Medicine Cancer Institute	Stanford	California	94305	Completed
University of Colorado Denver	Aurora	Colorado	80045	Completed
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	Completed
University of Miami Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Completed
Northwestern University	Chicago	Illinois	60611	Completed
University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	48109	Completed
Mayo Clinic Rochester	Rochester	Minnesota	55905	Completed
Washington University St. Louis	St Louis	Missouri	63130	Completed
Columbia University Medical Center	New York	New York	10032	Withdrawn
Thomas Jefferson Hospital - Sidney Kimmel Cancer Center	Philadelphia	Pennsylvania	19107	Completed
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15219	Completed
Vanderbilt University	Nashville	Tennessee	37203	Completed
MD Anderson Cancer Center	Houston	Texas	77030	Completed
UW Medicine-Seattle Cancer Care Alliance	Seattle	Washington	98109	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03016819, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 24, 2026 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03016819 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →